Please try another search
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
Name | Age | Since | Title |
---|---|---|---|
Liz Dallimore | - | 2022 | CEO, MD & Director |
David Blacker | - | - | Chairman of Clinical Advisory Committee |
Terence Budge | 71 | 2021 | Independent Non-Executive Director |
Elizabeth McCall | - | 2020 | Independent Non-Executive Director |
Tim Phillips | - | - | Member of Clinical Advisory Committee |
Geoffrey Richard Pocock | - | - | Non-Executive Director |
Geoffrey A. Donnan | - | - | Member of Clinical Advisory Committee |
Paul Bailey | - | - | Member of Clinical Advisory Committee |
Jeffery Saver | - | 2022 | Member of Clinical Advisory Committee |
Dianne M. Angus | 63 | 2023 | Non-Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review